论文部分内容阅读
氯吡格雷是治疗急性冠状动脉综合征的一种经典抗血小板药物,其对血小板的抑制具有个体差异性,但是部分患者不能从氯吡格雷的治疗中获益,从而提出了氯吡格雷抵抗的问题。基因多态性是氯吡格雷抵抗机制中的一个重要因素。本文旨在从基因多态性对氯吡格雷疗效影响的临床意义做一综述。
Clopidogrel is a classic antiplatelet agent for the treatment of acute coronary syndromes and has individual differences in inhibition of platelets but some patients do not benefit from the treatment of clopidogrel, thus proposing clopidogrel resistance problem. Gene polymorphism is an important factor in the mechanism of clopidogrel resistance. This article aims to review the clinical implications of the genetic polymorphisms for the efficacy of clopidogrel.